A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

NCT01491737 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pertuzumab
DRUG: Trastuzumab
DRUG: Aromatase Inhibitor
DRUG: Induction Chemotherapy

Sponsor

Hoffmann-La Roche